Wei-Dong Han
Overview
Explore the profile of Wei-Dong Han including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
49
Citations
1175
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Chen M, Li B, Wu Y, He Z, Xiong X, Han W, et al.
J Sci Food Agric
. 2023 Jul;
103(15):7798-7808.
PMID: 37463295
Background: This study developed an intelligent, pH-sensitive and amine-responsive colorimetric label based on chitosan, whey protein and thymol blue by controlling the pH value of the film-forming solution. The obtained...
2.
Zhai C, Yin L, Han W
World J Clin Cases
. 2022 Sep;
10(21):7474-7482.
PMID: 36157989
Background: Endometrial cancer (EC) is one of the most common cancers of the female reproductive tract, and the incidence is increasing rapidly. Immunotherapy using programmed cell death-1 (PD-1) inhibitors is...
3.
Chen H, Feng L, Li M, Ju H, Ding Y, Lan M, et al.
Oncologist
. 2021 Feb;
26(5):e780-e793.
PMID: 33543577
Background: The National Comprehensive Cancer Network's Rectal Cancer Guideline Panel recommends American Joint Committee of Cancer and College of American Pathologists (AJCC/CAP) tumor regression grading (TRG) system to evaluate pathologic...
4.
Li D, Li X, Zhou W, Huang Y, Liang X, Jiang L, et al.
Signal Transduct Target Ther
. 2019 Oct;
4:35.
PMID: 31637014
T cells in the immune system protect the human body from infection by pathogens and clear mutant cells through specific recognition by T cell receptors (TCRs). Cancer immunotherapy, by relying...
5.
Han X, Wang Y, Han W
Chronic Dis Transl Med
. 2019 Jan;
4(4):225-243.
PMID: 30603741
T cells engineered with the chimeric antigen receptor (CAR) are rapidly emerging as an important immunotherapy for hematologic malignancies. The anti-cluster of differentiation (CD)19 CAR-T cell therapy has been remarkably...
6.
Zhang W, Liu Y, Wang Y, Nie J, Guo Y, Wang C, et al.
Gene Ther
. 2018 Mar;
25(3):198-204.
PMID: 29599530
Excessive activated T-cell proliferation was observed in vivo in one patient after an anti-CD19-chimeric antigen receptor (CAR) T-cell infusion. The patient, who had chemotherapy refractory and CD19 diffuse large B-cell...
7.
Zhang W, Liu Y, Wang Y, Wang C, Yang Q, Zhu H, et al.
Signal Transduct Target Ther
. 2017 Dec;
2:17054.
PMID: 29263931
No abstract available.
8.
Zhang W, Wang Y, Guo Y, Dai H, Yang Q, Zhang Y, et al.
Signal Transduct Target Ther
. 2017 Dec;
1:16002.
PMID: 29263894
Patients with relapsed or refractory non-Hodgkin lymphoma have a dismal prognosis. Chimeric Antigen Receptor (CAR)-modified T cells (CART cells) that targeted CD20 were effective in a phase I clinical trial...
9.
Feng K, Guo Y, Liu Y, Dai H, Wang Y, Lv H, et al.
J Hematol Oncol
. 2017 Jan;
10(1):4.
PMID: 28057014
Background: Cholangiocarcinoma (CCA) is one of the most fatal malignant tumors with increasing incidence, mortality, and insensitivity to traditional chemo-radiotherapy and targeted therapy. Chimeric antigen receptor-modified T cell (CART) immunotherapy...
10.
Ma T, Luan S, Huang H, Sun X, Yang Y, Zhang H, et al.
Med Sci Monit
. 2016 Dec;
22:5206-5217.
PMID: 28035134
BACKGROUND CC chemokine receptor 7 (CCR7) expression is vital for cell migration to secondary lymphoid organs (SLOs). Our previous work showed that inducing CCR7 expression enabled syngeneic mesenchymal stem cells...